Alzheimer's Disease and Type 2 Diabetes Via Chronic Inflammatory Mechanisms

Overview

Journal Saudi J Biol Sci

Specialty Biology

Date 2015 Jan 7

PMID 25561876

Citations 30

Authors

Gohar Mushtaq

Jalaluddin A Khan

Taha A Kumosani

Mohammad A Kamal

Affiliations

Soon will be listed here.

Abstract

Recent evidence has indicated that type 2 diabetes mellitus (T2DM) increases the risk of developing Alzheimer's disease (AD). Therefore, it is crucial to investigate the potential common processes that could explain this relation between AD and T2DM. In the recent decades, an abundance of evidence has emerged demonstrating that chronic inflammatory processes may be the major factors contributing to the development and progression of T2DM and AD. In this article, we have discussed the molecular underpinnings of inflammatory process that contribute to the pathogenesis of T2DM and AD and how they are linked to these two diseases. In depth understanding of the inflammatory mechanisms through which AD and T2DM are associated to each other may help the researchers to develop novel and more effective strategies to treat together AD and T2DM. Several treatment options have been identified which spurn the inflammatory processes and discourage the production of inflammatory mediators, thereby preventing or slowing down the onset of T2DM and AD.

Citing Articles

Novel targets and therapies of metformin in dementia: old drug, new insights.

Cui W, Lv C, Geng P, Fu M, Zhou W, Xiong M Front Pharmacol. 2024; 15:1415740.

PMID: 38881878 PMC: 11176471. DOI: 10.3389/fphar.2024.1415740.

Evaluation of the biological efficiency of Terminalia chebula fruit extract against neurochemical changes induced in brain of diabetic rats: an epigenetic study.

El-Shamarka M, Aboulthana W, Omar N, Mahfouz M Inflammopharmacology. 2024; 32(2):1439-1460.

PMID: 38329710 PMC: 11006788. DOI: 10.1007/s10787-024-01428-9.

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus.

Pelle M, Zaffina I, Giofre F, Pujia R, Arturi F Int J Mol Sci. 2023; 24(14).

PMID: 37511061 PMC: 10379573. DOI: 10.3390/ijms241411301.

Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3β signaling.

Zaki M, El-Desouky S, Elsherbiny D, Salama M, Azab S Inflammopharmacology. 2022; 30(5):1871-1890.

PMID: 35922737 PMC: 9499917. DOI: 10.1007/s10787-022-01023-w.

Role of Histone Post-Translational Modifications in Inflammatory Diseases.

Lin Y, Qiu T, Wei G, Que Y, Wang W, Kong Y Front Immunol. 2022; 13:852272.

PMID: 35280995 PMC: 8908311. DOI: 10.3389/fimmu.2022.852272.

References

Feinstein R, Kanety H, Papa M, Lunenfeld B, Karasik A . Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993; 268(35):26055-8. View

Evans J, Goldfine I, Maddux B, Grodsky G . Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23(5):599-622. DOI: 10.1210/er.2001-0039. View

Cone J . Inflammation. Am J Surg. 2002; 182(6):558-62. DOI: 10.1016/s0002-9610(01)00822-4. View

Hotamisligil G, Shargill N, Spiegelman B . Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87-91. DOI: 10.1126/science.7678183. View

Rasool M, Malik A, Qazi A, Sheikh I, Manan A, Shaheen S . Current view from Alzheimer disease to type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2013; 13(3):533-42. DOI: 10.2174/18715273113126660167. View

Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Lawlor B . Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett. 1991; 129(2):318-20. DOI: 10.1016/0304-3940(91)90490-k. View

Heneka M, Reyes-Irisarri E, Hull M, Kummer M . Impact and Therapeutic Potential of PPARs in Alzheimer's Disease. Curr Neuropharmacol. 2012; 9(4):643-50. PMC: 3263458. DOI: 10.2174/157015911798376325. View

Griffin W, Sheng J, Royston M, Gentleman S, McKenzie J, Graham D . Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998; 8(1):65-72. PMC: 8098321. DOI: 10.1111/j.1750-3639.1998.tb00136.x. View

Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen A, Skinhoj P, Pedersen B . A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999; 54(7):M357-64. DOI: 10.1093/gerona/54.7.m357. View

10.

Takeda S, Sato N, Rakugi H, Morishita R . Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst. 2011; 7(6):1822-7. DOI: 10.1039/c0mb00302f. View

11.

Arvanitakis Z, Wilson R, Bienias J, Evans D, Bennett D . Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004; 61(5):661-6. DOI: 10.1001/archneur.61.5.661. View

12.

Iadecola C . Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004; 5(5):347-60. DOI: 10.1038/nrn1387. View

13.

Li Z, Zhang W, Sima A . Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007; 56(7):1817-24. DOI: 10.2337/db07-0171. View

14.

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T . Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2009; 32(9):1626-33. DOI: 10.1016/j.neurobiolaging.2009.10.009. View

15.

Liu L, Hong H, Liao J, Wang T, Wu J, Chen S . Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse. 2009; 63(8):636-42. DOI: 10.1002/syn.20644. View

16.

Di Napoli M, Papa F . Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003; 34(12):2922-9. DOI: 10.1161/01.STR.0000099124.84425.BB. View

17.

Di Gregorio G, Yao-Borengasser A, Rasouli N, Varma V, Lu T, Miles L . Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005; 54(8):2305-13. DOI: 10.2337/diabetes.54.8.2305. View

18.

Schmidt M, Duncan B, Sharrett A, Lindberg G, Savage P, Offenbacher S . Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353(9165):1649-52. DOI: 10.1016/s0140-6736(99)01046-6. View

19.

Sheng J, Bora S, Xu G, Borchelt D, Price D, Koliatsos V . Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis. 2003; 14(1):133-45. DOI: 10.1016/s0969-9961(03)00069-x. View

20.

Vozarova B, Weyer C, Lindsay R, Pratley R, Bogardus C, Tataranni P . High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51(2):455-61. DOI: 10.2337/diabetes.51.2.455. View